LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Strona główna・Stock List・Abeona Therapeutics Inc

Abeona Therapeutics Inc

Closed

4.3 -0.69

Buy Sell

Overview

Share price change

24h

Current

Min

4.29

Max

4.36

Key metrics
By Trading Economics
Income	-114M -5.2M
P/E Sector Avg	3.581 57.05
Profit margin	27,208.25
Employees	226

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+394.23% upside

Dividends
By Dow Jones
Next Earnings	14 maj 2026

Market Stats
By TradingEconomics
Market Cap	-9.4M 215M
Previous open	4.99
Previous close	4.3

Abeona Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 lis 2025, 19:31 UTC

Earnings

Major Market Movers

Abeona Therapeutics Shares Soar on Higher Demand for Zevaskyn

Peer Comparison

Price change

Abeona Therapeutics Inc Forecast

Price Target

By TipRanks

394.23% upside

12 Months Forecast

Average 21.4 USD 394.23%

High 28 USD

Low 17 USD

Based on 5 Wall Street analysts offering 12 month price targets forAbeona Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Abeona Therapeutics Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

Operating profit

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.